6 results on '"Rosati, Jessica"'
Search Results
2. Nitric oxide deficiency determines global chromatin changes in Duchenne muscular dystrophy.
- Author
-
Colussi, Claudia, Gurtner, Aymone, Rosati, Jessica, Illi, Barbara, Ragone, Gianluca, Piaggio, Giulia, Moggio, Maurizio, Lamperti, Costanza, D'Angelo, Grazia, Clementi, Emilio, Minetti, Giulia, Mozzetta, Chiara, Antonini, Annalisa, Capogrossi, Maurizio C., Puri, Pier Lorenzo, and Gaetano, Carlo
- Subjects
NITRIC oxide ,DYSTROPHIN ,HISTONES ,PHOSPHOPROTEIN phosphatases ,CELL differentiation ,GENE expression ,MUSCULAR dystrophy ,LABORATORY mice - Abstract
The present study provides evidence that abnormal patterns of global histone modification are present in the skeletal muscle nuclei of mdx mice and Duchenne muscular dystrophy (DMD) patients. A combination of specific histone H3 modifications, including Ser-10 phosphorylation, acetylation of Lys 9 and 14, and Lys 79 methylation, were found enriched in muscle biopsies from human patients affected by DMD and in late-term fetuses, early postnatal pups, or adult mdx mice. In this context, chromatin immunoprecipitation experiments showed an enrichment of these modifications at the loci of genes involved in proliferation or inflammation, suggesting a regulatory effect on gene expression. Remarkably, the reexpression of dystrophin induced by gentamicin treatment or the administration of nitric oxide (NO) donors reversed the abnormal pattern of H3 histone modifications. These findings suggest an unanticipated link between the dystrophin-activated NO signaling and the remodeling of chromatin. In this context, the regulation of class IIa histone deacetylases (HDACs) 4 and 5 was found altered as a consequence of the reduced NO-dependent protein phosphatase 2A activity, indicating that both NO and class IIa HDACs are important for satellite cell differentiation and gene expression in mdx mice. In conclusion, this work provides the first evidence of a role for NO as an epigenetic regulator in DMD. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
3. HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment.
- Author
-
Colussi, Claudia, Mozzetta, Chiara, Gurtner, Aymone, Illi, Barbara, Rosati, Jessica, Straino, Stefania, R!gone, Gianluca, Pescatori, Mario, Zaccagnini, Germana, Antonini, Annalisa, Minetti, Giulia, Martelli, Fabio, Piaggio, Giulia, GalIinari, Paola, SteinkuIher^7, Christian, Clementi, Emilio, DeIl'Aversana, Carmela, Altucci, Lucia, Mai, Antonello, and Capogrossi, Maurizio C.
- Subjects
TREATMENT of Duchenne muscular dystrophy ,NITRIC oxide ,HISTONE deacetylase ,DYSTROPHIN ,LABORATORY mice - Abstract
The overlapping histological and biochemical features underlying the beneficial effect of deacetylase inhibitors and NO donors in dystrophic muscles suggest an unanticipated molecular link among dystrophin, NO signaling, and the histone deacetylasEs (HDACs). Higher global deacetylase activity and selective increased expression of the class I histone deacetylase HDAC2 were detected in muscles of dystrophin-deficient MDX mice. In vitro and in vivo siRNA-mediated down-regulation of HDAC2 in dystrophic muscles was sufficient to replicate the morphological and functional benefits observed with deacetylase inhibitors and NO donors. We found that restoration of NO signaling in vivo. by adenoviralmediated expression of a constitutively active endothelial NOS mutant in MDX muscles, and in vitro, by exposing MDX-derived satellite cells to NO donors, resulted in HDAC2 blockade by cysteine S-nitrosylation. These data reveal a special contribution of HDAC2 in the pathogenesis of Duchenne muscular dystrophy and indicate that HDAC2 inhibition by NO-dependent S-nitrosylatión is important for the therapeutic response to NO donors in MDX mice. They also define a common target for independent pharmacological interventions in the treatment of Duchenne muscular dystrophy. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
4. Nitric Oxide Modulates Chromatin Folding in Human Endothelial Cells via Protein Phosphatase 2A Activation and Class II Histone Deacetylases Nuclear Shuttling.
- Author
-
Illi, Barbara, Dello Russo, Claudio, Colussi, Claudia, Rosati, Jessica, Pallaoro, Michele, Spallotta, Francesco, Rotili, Dante, Valente, Sergio, Ragone, Gianluca, Martelli, Fabio, Biglioli, Paolo, Steinkuhler, Christian, Gallinari, Paola, Mai, Antonello, Capogrossi, Maurizio C., and Gaetano, Carlo
- Subjects
NITRIC oxide ,CHROMATIN ,PHOSPHOPROTEIN phosphatases ,HISTONE deacetylase ,GENE expression ,NITROGEN compounds ,CHROMOSOMES ,AMIDASES - Abstract
The article focuses on human umbilical vein endothelial cell (HUVEC) nitric oxide (NO) which inhibited serum-induced histone acetylation and enhanced histone deacetylase (HDAC) activity. In using immunofluorescence and Western blot analyses, NO induced class II HDAC4 and 5 nuclear shuttling and class II HDACs selective inhibitor MC1568 rescued serum-dependent histone acetylation above control level in NO-treated HUVECs. It was noted that NO-dependent protein phosphatase 2A activation is significance to class II HDACs nuclear translocation.
- Published
- 2008
- Full Text
- View/download PDF
5. Histone deacetylase inhibitors: Keeping momentum for neuromuscular and cardiovascular diseases treatment
- Author
-
Colussi, Claudia, Illi, Barbara, Rosati, Jessica, Spallotta, Francesco, Farsetti, Antonella, Grasselli, Annalisa, Mai, Antonello, Capogrossi, Maurizio C., and Gaetano, Carlo
- Subjects
- *
HISTONE deacetylase , *NEUROMUSCULAR diseases , *CARDIOVASCULAR disease treatment , *MULTIDRUG resistance , *CYTOPLASMIC filaments , *APOPTOSIS , *ISCHEMIA , *NEURODEGENERATION , *THERAPEUTICS - Abstract
Abstract: Histone deacetylases (HDACs) are enzymes with a pleiotropic range of intracellular localizations and actions. They are principally involved in the withdrawal of acetyl-groups from a large number of nuclear and cytoplasmic proteins including nuclear core histones as well as cytoskeletal proteins and metabolically relevant enzymes. Initial findings indicated that HDAC inhibitors (DIs) could be successfully applied in a variety of cancer treatment protocols as a consequence of their anti-proliferative and pro-apoptotic properties. Recent observations, however, enlightened the important therapeutic effects of DIs in experimental animal models for arthritis, neurodegenerative and neuromuscular disorders, heart ischemia, cardiac hypertrophy, heart failure and arrhythmias. A small number of clinical trials are now open or planned for the near future to verify the therapeutic properties of DIs in non-cancer-related diseases. This review summarizes some of the most important observations and concepts aroused by the most recent experimental application of DIs to neuromuscular and cardiac diseases. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
6. A Nitric Oxide-dependent Cross-talk between Class I and III Histone Deacetylases Accelerates Skin Repair.
- Author
-
Spallotta, Francesco, Cencioni, Chiara, Stefania Straino, Nanni, Simona, Rosati, Jessica, Artuso, Simona, Manni, Isabella, Colussi, Claudia, Piaggio, Giulia, Martelli, Fabio, Valente, Sergio, Mai, Antonello, Capogrossi, Maurizio C., Farsetti, Antonella, and Gaetano, Carlo
- Subjects
- *
NITRIC oxide , *HISTONE deacetylase , *WOUND healing , *KERATINOCYTES , *CELL proliferation , *SKIN regeneration - Abstract
In a mouse model of skin repair we found that the class I-IIa histone deacetylase inhibitor trichostatin A accelerated tissue regeneration. Unexpectedly, this effect was suppressed by Sirtinol, a class III histone deacetylase (HDAC) (sirtuin)-selective inhibitor. The role of sirtuins (SIRTs) was then investigated by using resveratrol and a novel SIRT1-2-3 activator, the MC2562 compound we synthesized recently. Both resveratrol and MC2562 were effective in accelerating wound repair. The local administration of natural or synthetic SIRT activators, in fact, significantly accelerated skin regeneration by increasing keratinocyte proliferation. In vitro experiments revealed that the activation of SIRTs stimulated keratinocyte proliferation via endothelial NO synthase phosphorylation and NO production. In this condition, the class I member HDAC2 was found S-nitrosylated on cysteine, a post-transduction modification associated with loss of activity and DNA binding capacity. After deacetylase inhibitor or SIRT activator treatment, ChIP showed, in fact, a significant HDAC2 detachment from the promoter region of insulin growth factor I (IGF-I), fibroblast growth factor 10 (FGF- 10), and Epithelial Growth Factor (EGF), which may be the final recipients and effectors of the SIRT-NO-HDAC signaling cascade. Consistently, the effect of SIRT activators was reduced in the presence of NG-nitro-L-arginine methyl ester (L-NAME), a general inhibitor of NO synthesis. In conclusion, the NO-dependent cross-talk among class III and I histone deacetylases suggests an unprecedented signaling pathway important for skin repair. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.